kabutan

Noile-Immune Biotech Inc.(4893) Summary

4893
TSE Growth
Noile-Immune Biotech Inc.
161
JPY
0
(0.00%)
Dec 5, 2:13 pm JST
1.03
USD
Dec 5, 12:13 am EST
Result
PTS
outside of trading hours
160.1
Dec 5, 1:43 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.70
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
162 JPY 1.04 USD
Previous Close Dec 4
161 JPY 1.03 USD
High Dec 5, 9:00 am
162 JPY 1.04 USD
Low Dec 5, 10:52 am
158 JPY 1.01 USD
Volume
40,600
Trading Value
7.00M JPY 0.04M USD
VWAP
160.8 JPY 1.04 USD
Minimum Trading Value
16,100 JPY 103 USD
Market Cap
6.97B JPY 0.05B USD
Number of Trades
52
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Mid
1-Year Average
256
1-Year High Jul 2, 2025
8,956
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 333,500 1,079,000 3.24
Nov 21, 2025 343,500 1,119,900 3.26
Nov 14, 2025 395,500 1,144,300 2.89
Nov 7, 2025 420,900 1,132,600 2.69
Oct 31, 2025 413,600 1,141,700 2.76
Company Profile
Noile-Immune Biotech Inc. engages in the development of novel immunotherapies utilizing CAR-T cells for cancer treatment.
Sector
Pharmaceuticals
Noile-Immune Biotech Inc. focuses on developing novel immunotherapies utilizing CAR-T cells for cancer treatment. The company aims to develop effective CAR-T cell therapies for solid tumors using its proprietary PRIME technology. PRIME technology is a platform technology that can be applied to regenerative medicine, with the potential to achieve superior cancer treatment effects by activating immune cells within the patient's body. It promotes the infiltration and activation of immune cells into solid tumor tissues. Noile-Immune Biotech pursues two business models: in-house drug discovery and collaborative pipelines, with multiple pipelines in progress. The company is also conducting clinical trials targeting solid tumors, exploring new possibilities in cancer immunotherapy.